ArticleJapanese journal of ophthalmology2026
Evaluation of anterior scleral thickness in pachychoroid pigment epitheliopathy, central serous chorioretinopathy and pachychoroid neovasculopathy.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare anterior scleral thickness (AST) among pachychoroid pigment epitheliopathy (PPE), central serous chorioretinopathy (CSC), pachychoroid neovasculopathy (PNV) and healthy controls. STUDY
designRetrospective cross-sectional study.
methodsThis single-center, retrospective cross-sectional study included 73 eyes of 72 patients with pachychoroid spectrum disease (PPE (n = 35), CSC (n = 25), PNV (n = 12)) and 29 control eyes. All participants underwent comprehensive ophthalmic examination and swept-source optic coherence tomography (OCT) (Topcon DRI-OCT Triton). Choroidal thickness (CT) was measured subfoveally, at 500 and 1000 μm nasal/temporal to the fovea, and sublesionally. AST was measured with the anterior segment mode 6 mm posterior to the scleral spur in four quadrants.
resultsCT was significantly greater in CSC than in PPE, PNV, and controls at all macular locations (all p < 0.001). Sublesional CT differed among pachychoroid groups (p = 0.005), with CSC thicker than PPE (p = 0.002) and PNV (p = 0.011); PPE and PNV did not differ (p = 1.000). Anterior scleral thickness was significantly greater in all quadrants in the pachychoroid groups compared with controls (p < 0.001). Superior AST was greater in PPE than PNV (p = 0.044); other inter-pachychoroid comparisons were not significant (p > 0.05). In multivariate linear regression model, the presence of pachychoroid spectrum disease was independently associated with thicker AST after adjustment for age, sex, AXL, and SE (p< 0.001 for all quadrants).
conclusionEyes with pachychoroid spectrum disease exhibit increased AST relative to controls, while diffuse CT thickening is most pronounced in CSC. These findings support a pathophysiologic association between scleral structure and choroidal venous overload in pachychoroid disorders and highlight AST as a potential structural biomarker.
Indexed as
Identifiers
42287503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.